Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Series B lands $135mm for Beam Therapeutics

07 Mar 2019

Executive Summary

Beam Therapeutics Inc. (developing genetic medicines through base editing) raised $135mm in its Series B financing to first-time backers Redmile Group, Cormorant Asset Management, GV, and Altitude Life Science Ventures, and returning shareholders F-Prime Capital, ARCH Venture Partners, Eight Roads Ventures, and Omega Funds, as well as undisclosed investors. The company will use the funds to advance next-generation CRISPR technologies, expand its pipeline, and expand its scientific and technical leadership.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By